Here is the last news from Europe.
http://europa.eu/rapid/press-release_MEX-13-0806_en.htm#PR_metaPressRelease_bottom
Mergers: Commission clears acquisition of Bausch & Lomb by Valeant
The European Commission has approved under the EU Merger Regulation the acquisition of the global eye health company Bausch & Lomb Holdings Inc. of the Unites States by Valeant Pharmaceuticals International Inc. of Canada. The parties' activities overlap in the markets for ophthalmic pharmaceuticals, consumer vision products and ophthalmic medical products. The Commission's investigation found that the overlaps in consumer vision and ophthalmic medical products segments were very limited; therefore the transaction would not have an appreciable effect on competition in these markets. In ophthalmic pharmaceuticals, the Commission found that the parties' products were not close substitutes and that a number of strong competitors would remain in the market after the merger. The Commission therefore concluded that the transaction would not raise competition concerns. The case was examined under the normal merger review procedure. More information is available on the Commission's competition website, in the public case register under the case number M.6969 .
http://europa.eu/rapid/press-release_MEX-13-0806_en.htm#PR_metaPressRelease_bottom
Mergers: Commission clears acquisition of Bausch & Lomb by Valeant
The European Commission has approved under the EU Merger Regulation the acquisition of the global eye health company Bausch & Lomb Holdings Inc. of the Unites States by Valeant Pharmaceuticals International Inc. of Canada. The parties' activities overlap in the markets for ophthalmic pharmaceuticals, consumer vision products and ophthalmic medical products. The Commission's investigation found that the overlaps in consumer vision and ophthalmic medical products segments were very limited; therefore the transaction would not have an appreciable effect on competition in these markets. In ophthalmic pharmaceuticals, the Commission found that the parties' products were not close substitutes and that a number of strong competitors would remain in the market after the merger. The Commission therefore concluded that the transaction would not raise competition concerns. The case was examined under the normal merger review procedure. More information is available on the Commission's competition website, in the public case register under the case number M.6969 .
